Citalopram is a widely prescribed antidepressant belonging to the class of selective serotonin reuptake inhibitors (SSRIs). Approved by the U.S. Food and Drug Administration (FDA) in 1998, it is primarily used to treat major depressive disorder (MDD) and, in some cases, other anxiety-related conditions. This report provides a concise overview of its pharmacology, therapeutic indications, dosing, common side effects, safety considerations, and clinical efficacy.

Pharmacology and Mechanism of Action

Citalopram exerts its antidepressant effects by selectively inhibiting the reuptake of serotonin (5-hydroxytryptamine, 5-HT) at the presynaptic neuron, thereby increasing the concentration of serotonin in the synaptic cleft. This enhanced serotonergic neurotransmission is believed to alleviate depressive symptoms. Unlike some older antidepressants, citalopram has minimal affinity for other neurotransmitter receptors such as histamine, dopamine, or acetylcholine, which accounts for its generally favorable side-effect profile compared to tricyclic antidepressants (TCAs) or monoamine oxidase inhibitors (MAOIs). Citalopram is a racemic mixture, but its therapeutic activity is primarily attributed to the S-enantiomer, escitalopram, which is also marketed separately as a more potent and selective alternative.

Therapeutic Indications

The primary indication for citalopram is major depressive disorder in adults. It is also commonly used off-label for the treatment of generalized anxiety disorder (GAD), panic disorder, obsessive-compulsive disorder (OCD), and social anxiety disorder, although evidence for these uses is less robust than for escitalopram or other SSRIs. In some countries, citalopram is approved for the treatment of agoraphobia and premenstrual dysphoric disorder. Its effectiveness in elderly patients makes it a popular choice in geriatric psychiatry, though dose adjustments are required.

Dosing and Administration

Citalopram is available in tablet or oral solution form, typically taken once daily with or without food. For adults, the recommended starting dose is 20 mg per day, which may be increased to 40 mg per day based on clinical response. The maximum recommended dose is 40 mg per day in most guidelines due to concerns about QT interval prolongation at higher doses (60 mg or more). In elderly patients (≥65 years) or those with hepatic impairment, the maximum dose is often limited to 20 mg per day. Dose tapering is advised upon discontinuation to avoid withdrawal symptoms such as dizziness, nausea, and anxiety.

Common Side Effects

Like other SSRIs, citalopram is associated with a range of adverse effects, though many are transient and diminish over the first few weeks. Common side effects include nausea, dry mouth, somnolence or insomnia, increased sweating, sexual dysfunction (e.g., decreased libido, delayed ejaculation), and weight changes. Gastrointestinal disturbances, such as diarrhea or constipation, are also reported. Notably, citalopram has a lower incidence of weight gain compared to paroxetine, but a higher incidence of insomnia than fluoxetine. Sexual side effects can be distressing and may require dose adjustment or switching to another SSRI with a different profile, such as bupropion.

Serious Adverse Reactions and Contraindications

A significant concern with citalopram is its potential to cause QT interval prolongation, particularly at doses above 40 mg per day. This can predispose patients to dangerous cardiac arrhythmias such as torsades de pointes. Hence, citalopram is contraindicated in patients with congenital long QT syndrome, electrolyte imbalances, or concurrent use of other QT-prolonging drugs. Additionally, SSRIs, including citalopram, carry a black-box warning for increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults under 25 during initial treatment. Other serious risks include serotonin syndrome (especially when combined with other serotonergic agents), hyponatremia (particularly in elderly patients), and bleeding abnormalities due to reduced platelet serotonin uptake. Abrupt discontinuation can cause withdrawal syndrome; therefore, gradual tapering is essential.

Drug Interactions

Citalopram is metabolized primarily by the cytochrome P450 enzymes CYP2C19 and CYP3A4, with minor involvement of CYP2D6. Co-administration with potent inhibitors of CYP2C19 (e.g., omeprazole, esomeprazole) or CYP3A4 (e.g., ketoconazole, clarithromycin) can lead to increased plasma concentrations and risk of toxicity. Conversely, inducers such as rifampin may reduce efficacy. Caution is also warranted with other serotonergic drugs (e.g., MAOIs, triptans, St. John's wort) due to risk of serotonin syndrome. As mentioned, medications that prolong the QT interval (e.g., certain antiarrhythmics, antipsychotics, and macrolide antibiotics) should be avoided or used with close monitoring.

Efficacy and Clinical Considerations

Numerous randomized controlled trials and meta-analyses have established the efficacy of citalopram in treating moderate to severe depression, with response rates typically around 50–65% across 6–8 weeks of treatment. Its tolerability profile is generally better than TCAs but similar to other SSRIs. In head-to-head comparisons with escitalopram, the latter often shows slightly superior efficacy and faster onset, though citalopram remains a cost-effective alternative. One notable advantage of citalopram is its low propensity for drug–drug interactions via CYP2D6, making it useful in patients on multiple medications affected by that enzyme. However, its QT risk has led many clinicians to prefer other SSRIs for patients with cardiac risk factors.

Special Populations

In pregnancy, citalopram is classified as a Category C drug (US FDA definition; newer pregnancy categories apply outside the US). Data suggest a small increased risk of congenital heart defects with first-trimester exposure, as well as persistent pulmonary hypertension in the newborn with late-term use. Breastfeeding is generally considered acceptable with caution, as small amounts are excreted in milk. Use in children and adolescents is not FDA-approved but sometimes prescribed off-label; the risk of suicidal ideation requires careful monitoring. In elderly patients, lower doses and monitoring for hyponatremia and falls are recommended.

Conclusion

Citalopram remains a valuable and commonly prescribed SSRI for major depressive disorder, offering a balance of efficacy and tolerability. Its relatively simple dosing and once-daily administration enhance adherence. However, clinicians must remain vigilant about QT prolongation, drug interactions, and the need for gradual titration and tapering. While newer SSRIs and other antidepressant classes have expanded treatment options, citalopram’s long track record and favorable safety profile in many patients ensure its continued relevance in psychiatry.